Left atrial appendage closure: Six reasons why I wouldn't choose a percutaneous closure for my appendage

Area of Science:

• Cardiology
• Vascular Medicine
• Medical Devices

Background:

• The left atrial appendage is a major source of thrombi in non-valvular atrial fibrillation (AF).
• Non-vitamin K oral anticoagulants (NOACs) are effective for preventing embolic complications in AF.
• Guidelines suggest percutaneous left atrial appendage closure (LAAC) for AF patients with contraindications to long-term oral anticoagulant therapy (OAC).

Purpose of the Study:

• To provide an overview of key clinical trials comparing NOACs and LAAC.
• To evaluate the safety and efficacy of LAAC as an alternative stroke prevention strategy in AF.

Main Methods:

• Review of major clinical trials involving NOACs and LAAC.
• Analysis of data on embolic complication prevention and safety profiles.

Main Results:

• NOACs demonstrate safety and efficacy in preventing embolic events.
• LAAC is a viable option for patients unable to tolerate long-term OAC.

Conclusions:

• Both NOACs and LAAC are important strategies for stroke prevention in non-valvular AF.
• LAAC provides an alternative for specific patient populations with contraindications to OAC.